How nanoplastics may be impacting our long-term health
He says his research estimates that the amount of plastic in the brain could be roughly equal to the size of a plastic spoon.
"That is a lot," Campen explains to CBS News. "...The fact that it's getting worse over time is really the issue."
Scientists believe these microscopic particles, called nanoplastics, come from all the plastic people use and throw away. When plastic breaks down over time, it winds up in the food supply, the water we drink, and even the air we breathe.
A study last month in the Journal of the American Heart Association finds that people living near nanoplastic-polluted oceans are more likely to suffer from type 2 diabetes, heart disease, and stroke compared to those that lived near waters that have low levels of nanoplastics.
Campen's lab has found more plastic in the brains of people with dementia than those without dementia.
Now, research on these nanoplastics is moving out of the lab and into long-term clinical studies. "We have more evidence now for the effects of plastic on children's chronic disease then we do on food dyes," said Dr. Leonardo Trasande, a professor of pediatrics at New York University's Grossman School of Medicine. "And if we use the same evidence standard, we should be acting as fiercely on plastics in the food supply as we are on food dyes." Trasande is tracking plastics' impact on over 64,000 children, from pregnancy to adolescence, including on 8-year-old Jack Glaser.
"The amount of information that they're collecting is remarkable," Glaser's mother, Tammy Fried-Glaser, said. "They did cognitive studies on Jack, you know, height and weight and sonograms, and beyond."
So far, Trasande's research has linked plastics to health problems like hormonal issues with fertility, premature birth, cognitive abnormalities and cardiovascular disease.
"Literally the particle is a problem — because it's a foreign body in a tissue," Trasande said. "It might thrash the lining of the coronary artery, contributing to clogging...These are toxic drug delivery systems."
While the details are still emerging, experts agree that less plastic is the way forward.
While many believe 10,000 steps a day is optimal, new study suggests different
DOJ's closed-door meetings with Ghislaine Maxwell fuels pardon speculation
The impact of nanoplastics on long-term health
Solve the daily Crossword
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
a few seconds ago
- Medscape
Every Step Counts, But Do You Really Need 10,000?
Good news for the sole: Contrary to popular wisdom, people can get the same health benefits from walking 7000 steps a day as they do from walking 10,000 paces, according to a comprehensive review and meta-analysis published in The Lancet Public Health . 'For all outcomes, health benefits continued to accrue until around 7000 steps,' said Katherine Owen, PhD, biostatistician at the University of Sydney, Sydney, Australia, who led the review. 'After 7000 steps, benefits either plateaued or there were very small additional benefits.' Owen and her colleagues reviewed 57 studies and conducted a meta-analysis on 31 of them, examining the relationship between health and physical activity based on daily steps. The researchers looked at nine different health outcomes: all-cause mortality, the incidence of and deaths from cardiovascular disease, dementia, cancer incidence and mortality, the incidence of type 2 diabetes, depressive symptoms, and falls. Every outcome showed improvement as the amount of daily activity increases, but for most people the benefits tapered off at around 5000-7000 steps per day. Compared with taking just 2000 steps per day, walking approximately 7000 steps per day reduced all-cause mortality by 47% and decreased the incidence of cardiovascular disease by 25%, of cancer by 6%, of type 2 diabetes by 14%, of dementia by 38%, of depression by 22%, and of falls by 28%. The study also highlighted that even modest step counts of around 4000 per day were beneficial compared with lower activity of just 2000 steps. 'Every step counts,' Owen said. 'All physical activity is beneficial, but increasing daily steps to around 7000 steps is optimal to improve all health outcomes.' The conventional wisdom that 10,000 steps per day was the optimal amount has no real basis in fact, said I-Min Lee, MD, epidemiologist at Harvard Medical School, Boston, who was the first to show that the health benefits of daily exercise leveled off after 7500 steps. 'There are quite a bit of data now showing that fewer than 10,000 steps per day brings health benefits,' she said. Lee said that most studies to date have focused on all-cause mortality and cardiovascular health. The new study expands the evidence to other health outcomes, although the data for some conditions, such as diabetes, are relatively sparse. Current guidelines for physical activity, such as those from the US Department of Health and Human Services, recommend 150 minutes per week of moderate-to-vigorous physical activity. However, due to lack of evidence at the time of publication, these guidelines do not include daily step targets. As step tracking technologies have become more common, and data on step-based activity have improved, Lee wants future guidelines to incorporate step targets. 'I don't believe they should replace time targets, since not everybody wants to track their steps,' she said. 'But they should be included.' Owen and Lee declared having no competing interests.
Medscape
31 minutes ago
- Medscape
More Data Cement COVID's Impact on Patients With Cancer
TOPLINE: New data confirm the impact COVID infection can have on patients with cancer and identified several risk factors associated with hospitalization and death. Receipt of chemotherapy as well as a baseline history of stroke, atrial fibrillation, or pulmonary embolism were each associated with nearly double the risk for COVID-related hospitalization. Prior vaccination halved this risk. Older age and earlier hospitalization were associated with a greater risk for death. METHODOLOGY: Patients undergoing active cancer treatment are at increased risk for severe COVID-19 due to immunosuppression, but risk factors for hospitalization and death are not well-defined. Researchers conducted a prospective cohort study involving 1572 patients with cancer (median age, 60 years; 53.4% women), enrolled within 14 days of a positive SARS-CoV-2 test; participants had received active treatment for cancer within 6 weeks before testing or had undergone prior stem cell transplant or CAR T-cell therapy. Patient screening and enrollment took place between May 2020 and February 2022. Treatments included chemotherapy (34.3%), targeted therapy (27.7%), and immunotherapy (10.6%). Breast (23.6%) and lung (13.9%) cancers were the most common cancer types. Overall, 64% of participants had metastatic disease, and at enrollment, 64% had not received a COVID vaccine. Study outcomes were COVID-related hospitalization or death. Risk factors for hospitalization and for death among hospitalized patients were evaluated separately. TAKEAWAY: At 90 days after an initial positive test, COVID-related mortality was 3% and remained stable at subsequent follow-ups. The highest incidence occurred in patients with lymphoma, followed by those with acute leukemia or lung cancer; the lowest incidence occurred in those with other types of solid tumors and blood cancers. Hospitalization for COVID-19 occurred in 18.4% of patients within 90 days of enrollment. The risk for hospitalization was elevated among patients who received chemotherapy (hazard ratio [HR], 1.97) and those with a history of stroke, atrial fibrillation, and pulmonary embolism (HR, 1.78). Vaccination prior to infection reduced the risk for hospitalization by nearly half (HR, 0.52). Hospitalization for COVID-19 within 30 days of infection was associated with an increased risk for death (HR, 14.6). Among patients hospitalized for COVID within 30 days, age 65 years or older was the only significant predictor of COVID-specific death (HR, 3.49). Over the 2-year follow-up, there were 1739 disruptions to cancer treatment; 50.7% of these were attributed to COVID-19, and most occurred within 30 days of a positive test. IN PRACTICE: 'The data from this prospective cohort study confirm and expand previous retrospective case series that have found factors, including hematologic cancers, chemotherapy receipt, and lung cancer, as associated with COVID-19 severity,' the authors of the study wrote, noting that the results 'showed that COVID-19 had a significant impact on patients with cancer, including hospitalization, treatment disruptions, and death.' SOURCE: This study, led by Brian I. Rini, MD, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, was published online in JAMA Oncology. LIMITATIONS: Information on specific strains was not available. This study lacked a control group of patients without COVID-19, which limited causal inference. Additionally, as participants were enrolled through the National Cancer Institute trial networks, generalizability to a broader population could be limited. DISCLOSURES: This study was funded in part by the Coronavirus Aid, Relief, and Economic Security Act and the National Cancer Institute National Clinical Trials Network, Experimental Therapeutics Clinical Trials Network, and Community Oncology Research Program grants via the U10 funding mechanism. Several authors declared receiving grants and/or personal fees and having other ties with various sources. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Yahoo
an hour ago
- Yahoo
MrFluffyFriend Launches XXXXL Calming Dog Bed for Large and Anxious Dogs
Over 600,000 dogs sleep better already — now available in 48 inch (120cm) & 56 inch (140cm) with up to 60% off and free shipping on Image by MrFluffyFriend LOS ANGELES, July 27, 2025 (GLOBE NEWSWIRE) -- MrFluffyFriend, a fast-growing U.S. pet wellness brand known for its calming products, announces the launch of its XXXXL Calming Dog Bed, specially designed for large breeds and dogs prone to anxiety. The oversized beds, now available in 120cm and 140cm, offer unmatched comfort and emotional relief thanks to premium materials and calming features rooted in behavioral science. Made with ultra-soft vegan faux fur, deep orthopedic padding, and a raised rim for added head and neck support, the XXXXL Calming Bed creates a soothing nest-like environment that helps dogs feel safe, supported, and calm — especially during fireworks, thunderstorms, or when left home alone. 'We've helped over 600,000 dogs sleep better with our calming beds,' says a MrFluffyFriend spokesperson. 'Our community asked for something big enough for their Labradors, Golden Retrievers, Huskies — and we listened. This launch is all about showing that big dogs deserve big comfort, too.' According to veterinarians, over 70% of dogs experience anxiety at some point, which can lead to restlessness, whining, and destructive behavior. MrFluffyFriend's calming design mimics a mother's touch, helping to trigger the release of serotonin and reduce stress naturally. Key Features: Sizes: XXXL (48 in / 120 cm) and XXXXL (56 in / 140 cm) Raised rim for orthopedic support and security Ultra-soft faux fur mimics a mother's touch Machine washable cover + water-resistant, non-slip base Hypoallergenic and pet-safe materials Ideal for large breeds and multi-dog households The launch is accompanied by a limited-time offer of up to 60% off, free shipping across the U.S., and a 30-day risk-free trial, making it easier than ever for pet parents to try the product. Early feedback has been overwhelmingly positive, with customers praising the bed's luxurious size, fluffiness, and noticeable calming effect. Some report their dogs sleep longer, bark less, and even retreat to the bed during stressful moments like vet visits or fireworks. About MrFluffyFriend Founded with a mission to help pets feel safe, calm, and loved, MrFluffyFriend is a pet lifestyle brand trusted by dog lovers in over 25 countries. From calming beds to wellness accessories, every product is developed with science-backed design and premium materials to ensure pets thrive — emotionally and physically. Learn more at Media Contact: Thomas, H. info@ A photo accompanying this announcement is available at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
